Greenwich LifeSciences, Inc. (GLSI) Stock Analysis
Greenwich LifeSciences is a high-risk, high-upside clinical biotech where one Phase III breast cancer vaccine candidate could either unlock multibillion-dollar value or collapse the equity thesis.
Overview
Greenwich LifeSciences is a pre-revenue, single-asset oncology biotech whose future depends almost entirely on GLSI-100, a GP2 peptide immunotherapy for preventing HER2-positive breast cancer recurrence. Phase IIb data showed 100% five-year disease-free survival in HER2-positive patients versus 88.8% in controls, with a highly favorable safety profile. The opportunity is substantial, but commercialization depends on Phase III success, regulatory approval, and either direct U.S. launch, licensing, partnership, or acquisition by a larger pharmaceutical company.